These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 34479103)

  • 41. Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase.
    Kawahata W; Asami T; Kiyoi T; Irie T; Kashimoto S; Furuichi H; Sawa M
    J Med Chem; 2021 Oct; 64(19):14129-14141. PubMed ID: 34529443
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of BTK inhibitors for the treatment of B-cell malignancies.
    Kim HO
    Arch Pharm Res; 2019 Feb; 42(2):171-181. PubMed ID: 30706214
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton's tyrosine kinase inhibitors.
    Sakthivel S; Habeeb SKM
    J Biomol Struct Dyn; 2018 Dec; 36(16):4320-4337. PubMed ID: 29293382
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of Bruton's tyrosine kinase in the immune system and disease.
    McDonald C; Xanthopoulos C; Kostareli E
    Immunology; 2021 Dec; 164(4):722-736. PubMed ID: 34534359
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
    da Cunha-Bang C; Niemann CU
    Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
    Xue Y; Song P; Song Z; Wang A; Tong L; Geng M; Ding J; Liu Q; Sun L; Xie H; Zhang A
    J Med Chem; 2018 May; 61(10):4608-4627. PubMed ID: 29715023
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of Bruton's Tyrosine Kinase Inhibitors for Rheumatoid Arthritis.
    Lv J; Wu J; He F; Qu Y; Zhang Q; Yu C
    Curr Med Chem; 2018; 25(42):5847-5859. PubMed ID: 29546831
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.
    Rhodes JM; Mato AR
    Drug Des Devel Ther; 2021; 15():919-926. PubMed ID: 33688166
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bruton's Tyrosine Kinase Targeting in Multiple Myeloma.
    Von Suskil M; Sultana KN; Elbezanti WO; Al-Odat OS; Chitren R; Tiwari AK; Challagundla KB; Srivastava SK; Jonnalagadda SC; Budak-Alpdogan T; Pandey MK
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071917
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.
    Pan Y; Chiu YH; Chiu SC; Cho DY; Lee LM; Wen YC; Whang-Peng J; Hsiao CH; Shih PH
    Anticancer Res; 2020 Nov; 40(11):6093-6099. PubMed ID: 33109547
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of Tricyclic Pyranochromenone as Novel Bruton's Tyrosine Kinase Inhibitors with in Vivo Antirheumatic Activity.
    Cho H; Lee E; Kwon HA; Seul L; Jeon HJ; Yu JH; Ryu JH; Jeon R
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33113810
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.
    Wang C; Li S; Meng Q; Sun X; Li H; Shu X; Sun H; Liu K; Liu Z; Ma X
    Bioorg Med Chem; 2018 Aug; 26(14):4179-4186. PubMed ID: 30006143
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Revealing the Role of the Arg and Lys in Shifting Paradigm from BTK Selective Inhibition to the BTK/HCK Dual Inhibition - Delving into the Inhibitory Activity of KIN-8194 against BTK, and HCK in the Treatment of Mutated
    Elamin G; Aljoundi A; Alahmdi MI; Abo-Dya NE; Soliman MES
    Anticancer Agents Med Chem; 2024; 24(11):813-825. PubMed ID: 36752293
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of Novel Bruton's Tyrosine Kinase PROTACs with Enhanced Selectivity and Cellular Efficacy.
    Li YQ; Lannigan WG; Davoodi S; Daryaee F; Corrionero A; Alfonso P; Rodriguez-Santamaria JA; Wang N; Haley JD; Tonge PJ
    J Med Chem; 2023 Jun; 66(11):7454-7474. PubMed ID: 37195170
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bruton's TK inhibitors: structural insights and evolution of clinical candidates.
    Xing L; Huang A
    Future Med Chem; 2014 Apr; 6(6):675-95. PubMed ID: 24895895
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies.
    Alu A; Lei H; Han X; Wei Y; Wei X
    J Hematol Oncol; 2022 Oct; 15(1):138. PubMed ID: 36183125
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of Intermolecular Interactions of Irreversible and Reversible Inhibitors with Bruton's Tyrosine Kinase via Molecular Dynamics Simulations.
    Yu X; Qiu S; Sun D; Guo P; Li Q
    Molecules; 2022 Nov; 27(21):. PubMed ID: 36364276
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment.
    Good L; Benner B; Carson WE
    Cancer Immunol Immunother; 2021 Sep; 70(9):2439-2451. PubMed ID: 33818636
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
    Ringheim GE; Wampole M; Oberoi K
    Front Immunol; 2021; 12():662223. PubMed ID: 34803999
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
    Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.